For Immediate Release
Chicago, IL – September 8, 2026 – Stocks in this week’s article are EuroDry Ltd. EDRY, RCM Technologies Inc. RCMT, Assembly Biosciences Inc. ASMB, Delcath Systems Inc. DCTH and National Energy Services Reunited Corp. NESR.
5 Stocks with Recent Price Strength Buoyed by a Strong August
U.S. stock markets ended August on a positive note after a mixed June and July. The Dow was up more than 1%, marking its fifth consecutive monthly winning streak. The S&P 500 and the Nasdaq Composite advanced 2.6% and 3.9%, respectively.
Both the S&P 500 and the Nasdaq Composite posted their first monthly advance since May. Moreover, the Dow and the S&P 500 recorded their new all-time highs both on an intraday and closing basis, early last month.
As a result, a few stocks have shown price strength. We have primarily targeted stocks that have recently been on a bull run. These stocks have a high chance of carrying the momentum forward.
Five such stocks are — EuroDry Ltd., RCM Technologies Inc., Assembly Biosciences Inc., Delcath Systems Inc. and National Energy Services Reunited Corp.
If a stock is continuously witnessing an uptrend, there must be a solid reason, or it would probably have crashed. So, looking at stocks capable of beating the benchmark that they have set for themselves seems rational.
However, recent price strength alone cannot create magic. Therefore, other relevant parameters are needed to create a successful investment strategy.
Here’s how you should create the screen to shortlist the current as well as the potential winners.
Let’s discuss five out of those 12 stocks here:
EuroDry is an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes. EDRY owns and operates drybulk carriers that transport major bulks, such as iron ore, coal, and grains, and minor bulks, including bauxite, phosphate, and fertilizers.
The stock price of EDRY has soared 109.3% in the past four weeks. It has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 35.1% over the last 30 days.
RCM Technologies is a national provider of business, technology and resource solutions in information technology and professional engineering to customers in the corporate and government sectors.
RCMT has grown its information technology competencies in the areas of resource augmentation, e-business, Enterprise Resource Planning support, network and infrastructure support and knowledge management. RCMT's engineering expertise is in the form of technical design, field engineering, field support, procedures development and project and program management.
The stock price of RCM Technologies has jumped 42.9% over the past four weeks. The company has an expected earnings growth rate of 22.8% for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 13.3% over the last 30 days.
Assembly Biosciences is a biopharmaceutical company that develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. ASMB’s product portfolio consists of two late-stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence.
ASMB is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections.
The stock price of Assembly Biosciences has surged 38.4% in the past four weeks. It has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 20% over the last 30 days.
Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers in the United States and Europe. DCTH’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
DCTH’s clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic-dominant uveal melanoma to investigate objective response rate in metastatic uveal melanoma.
The stock price of Delcath Systems has climbed 31.3% in the past four weeks. It has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved more than 100% over the last 30 days.
National Energy Services is one of the largest national oilfield services providers in the MENA and Asia Pacific regions. NESR helps its customers unlock the full potential of their reservoirs by providing production services such as cementing, coiled tubing, filtration, completions, stimulation and fracturing, and nitrogen services.
NESR also helps its customers to access the reservoirs in a smarter and faster manner by providing drilling and evaluation services like drilling downhole tools, directional drilling, fishing tools, testing services, wireline, slickline, fluids and rig services.
The stock price of NESR has rallied 23.4% in the past four weeks. It has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 4.6% over the last 30 days.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2984957/5-stocks-with-recent-price-strength-buoyed-by-a-strong-august
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report
Assembly Biosciences, Inc. (ASMB): Free Stock Analysis Report
RCM Technologies, Inc. (RCMT): Free Stock Analysis Report
National Energy Services Reunited (NESR): Free Stock Analysis Report
EuroDry (EDRY): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).